Patient-reported Outcomes in Subjects with Neuropathic Pain Receiving Pregabalin: Evidence from Medical Practice in Primary Care Settings

Pain Medicine

Volumn 11, Issue 5, 2010, Pages 719-731

  Navarro, Ana ^a   Saldaña, María T ^b   Pérez, Concepción ^c   Torrades, Sandra ^d   Rejas, Javier ^e  

^a Puerta Del Ángel Primary Care Center   (Spain)

^b Primary Care Health Centre Raices   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d European Biometrics Institute   (Spain)

^e PFIZER INC   (United States)

Author keywords

Clinically Meaningful; Medical Practice; Pain; Patient reported Outcomes; Pregabalin; Primary Care Settings

Indexed keywords

AMITRIPTYLINE; DICLOFENAC; DIPYRONE; GABAPENTIN; IBUPROFEN; KETOROLAC; PARACETAMOL; PREGABALIN; TRAMADOL; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; MONOTHERAPY; MULTICENTER STUDY; NEUROPATHIC PAIN; PAIN ASSESSMENT; PRIMARY MEDICAL CARE; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; COMPLICATION; HEALTH STATUS; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NEURALGIA; PAIN MEASUREMENT; PRIMARY HEALTH CARE; PROSPECTIVE STUDY; QUESTIONNAIRE; SLEEP DISORDERS;

ADULT; AGED; ANALGESICS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HEALTH STATUS; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEURALGIA; PAIN MEASUREMENT; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SLEEP DISORDERS; TREATMENT OUTCOME;

EID: 77953710225     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2010.00824.x     Document Type: Article

References (56)

1. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002, 18:350-4.
2. Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain 2007, 23:143-9.
3. Gore M, Brandenburg NA, Dukes E. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage 2005, 30:374-85.
4. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: A novel treatment approach. Clin J Pain 2007, 23:15-22.
5. Cornwall A, Donderi DC. The effect of experimentally induced anxiety on the experience of pressure pain. Pain 1988, 35:105-13.
6. Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev 2004, 8:119-32.
7. Wilson KG, Eriksson MY, D'Eon JL, Mikail SF, Emery PC. Major depression and insomnia in chronic pain. Clin J Pain 2002, 18:77-83.
8. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. QJM 1998, 91:733-7.
9. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: Results from a cross-sectional survey. Eur J Pain 2006, 10:127-35.
10. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: The patients' perspectives. J Pain 2006, 7:892-900.
11. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004, 5:143-9.
12. Currie CJ, Poole CD, Woehl A. The financial costs of healthcare treatment for people with Type 1 or Type 2 diabetes in the UK with particular reference to differing severity of peripheral neuropathy. Diabet Med 2007, 24:187-94.
13. Harden N, Cohen M. Unmet needs in the management of neuropathic pain. J Pain Symptom Manage 2003, 25(5):S12-7. suppl
14. Rodríguez MJ, García AJA. Registry of the aetiology and costs of neuropathic pain in pain clinics: Results of the Registry of aEtiologies and Costs (REC) in Neuropathic Pain Disorders Study. Clin Drug Invest 2007, 27:771-82.
15. Tolle T, Xu X, Sadosky AB. Painful diabetic neuropathy: A cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications 2006, 20:26-33.
16. Tolle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: Results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. Pain Pract 2006, 6:153-60.
17. van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006, 35:132-7.
18. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: An evidence based proposal. Pain 2005, 118:289-305.
19. Attal N, Cruccu G, Haanpää M. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006, 13:1153-69. EFNS Task Force
20. Moulin DE, Clark AJ, Gilron I. Pharmacological management of chronic neuropathic pain-Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007, 12:13-21. Canadian Pain Society
21. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: A novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007, 29:26-48.
22. Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: Current evidence and future directions. Curr Opin Anaesthesiol 2007, 20:456-72.
23. Stolley PD, Laporte J. The public health, the university, and pharmacoepidemiology. Pharmacoepidemiology 2000, 75-89. Strom BL, ed., 3rd, edition, Chichester, UK, John Wiley & Sons
24. Gallagher RM. Naturalistic study designs in samples with refractory pain: Advantages and limitations. Pain Med 2004, 5:143-5.
25. Freynhagen R, Grond S, Schüpfer G. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract 2007, 61:1989-96.
26. Baron R, Brunnmüller U, Brasser M, May M, Binder A. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: Open-label, non-comparative, flexible-dose study. Eur J Pain 2008, 12:850-8.
27. Navarro A, Saldaña MT, Pérez C, Masramon X, Rejas J. Health, non-health resources utilization and costs of treating refractory peripheral neuropathic pain (NeP) in primary care setting (PCS) under routine medical practice in Spain. Value Health 2007, 10:A465. abstract
28. Perez C, Galvez R, Huelbes S. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes 2007, 5:66.
29. Bouhassira D, Attal N, Fermanian J. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004, 108:248-57.
30. Bouhassira D, Attal N, Alchaar H. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005, 114:29-36.
31. Melzack R. The short-form McGill Pain Questionnaire. Pain 1987, 30(2):191-7.
32. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Intl Clin Psychopharmacol 1996, 11:S89-95. suppl
33. Hays RD, Stewart AL. Sleep measures. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach 1992, 235-59. Stewart AL, Ware JE. eds., Durham, NC, Duke University Press
34. Rejas J, Ribera MV, Ruiz M, Masrramon X. Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain. Eur J Pain 2007, 11:329-40.
35. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-70.
36. EuroQol-A new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990, 16:199-208. EuroQol Group
37. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989, 27:S178-89.
38. Collet J, Boivin J. Bias and confounding in pharmacoepidemiology. Pharmacoepidemiology 2000, 765-84. Strom BL, ed., 3rd, edition, Chichester, UK, John Wiley & Sons
39. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: An overview of recent guidelines. Am J Med 2009, 122(10):S22-32. suppl
40. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004, 110:628-38.
41. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: A randomized controlled trial. Neurology 2004, 63:2104-10.
42. Richter RW, Portenoy R, Sharma U. Relief of painful diabetic peripheral neuropathy with pregabalin: A randomized, placebo-controlled trial. J Pain 2005, 6:253-60.
43. Dworkin RH, Corbin AE, Young JP. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2003, 60:1274-83.
44. Sabatowski R, Galvez R, Cherry DA. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. Pain 2004, 109:26-35. 1008-045 Study Group
45. van Seventer R, Feister HA, Young JP. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: A 13-week, randomized trial. Curr Med Res Opin 2006, 22:375-84.
46. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005, 115:254-63.
47. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003, 105:71-8.
48. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: A randomized controlled trial. Neurology 2003, 60:927-34.
49. Gilron I, Bailey JM. Trends in opioid use for chronic neuropathic pain: A survey of patients pursuing enrollment in clinical trials. Can J Anaesth 2003, 50:42-7.
50. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain 2002, 18:22-7.
51. Gilron I, Bailey JM, Tu D. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005, 352:1324-34.
52. Simpson DA. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromusc Dis 2001, 3:53-62.
53. Gilron I, Bailey JM, Tu D. Nortriptyline and gabapentalone and in combination for neuropathic pain: A double-blind, randomised controlled crossover trial. Lancet 2009, 374:1252-61.
54. Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000, 16:188-92.
55. Khoromi S, Cui L, Nackers L, Max MB. Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain. Pain 2007, 130:66-75.
56. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: A practical guide for the clinician. CMAJ 2006, 175:265-75.